Aug. 30, 2012, 8:16 AMJ&J (JNJ) unit Janssen Biotech buys the global licensing rights to cancer agent daratumumab from Danish biotech Genmab in a deal that could eventually be worth over $1.1B. Janssen is paying $55M upfront and will make further payments following the achievement of development, regulatory and sales milestones. J&J is also investing $80M in Genmab in return for a 10.7% stake. (PR) | Aug. 30, 2012, 8:16 AM | Comment!
GNMSF vs. ETF Alternatives
Other News & PR